19 Sep, 2018

CIRCULOGENE Expands Testing Menu with Somatic BRCA1/2 Blood Testing

CIRCULOGENE Expands Testing Menu with Somatic BRCA1/2 Blood Testing Enables paired somatic-germline testing, broadens targeted treatment population for breast, ovarian, pancreatic and prostate cancers   BIRMINGHAM, Ala. – CIRCULOGENE, advancing precision medicine through molecular genetics testing, has [...]

19 Jun, 2018

CIRCULOGENE’s Molecular Testing Can Potentially Improve Management of Advanced Ovarian Cancer Patients

CIRCULOGENE’s Molecular Testing Can Potentially Improve Management of Advanced Ovarian Cancer Patients Independent UAB study demonstrates potential value of company’s molecular testing in noninvasive, serial tracking of genomic changes in treatment-resistant ovarian cancer BIRMINGHAM, Ala.– [...]

29 May, 2018

REQUEST FOR APPLICATIONS CIRCULOGENE – RESEARCH SAMPLE PROFILING PILOT AWARD PROGRAM

REQUEST FOR APPLICATIONS CIRCULOGENE – RESEARCH SAMPLE PROFILING PILOT AWARD PROGRAM Applications due: 5pm EST on August 1, 2018 Award announcements: anticipated by September 15, 2018 Pilot Award Details: Made possible by CIRCULOGENE, this pilot [...]

3 Jan, 2018

CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory

CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory Company expands single-blood-tube, cancer-targeted therapy and immunotherapy testing to parts of Europe, Africa, the Middle East and Commonwealth of Independent States (CIS) [...]

20 May, 2016

Circulogene Announces Four Abstracts Accepted for ASCO 2016 Conference

Circulogene Announces Four Abstracts Accepted for ASCO 2016 Conference Research involving Circulogene’s single-drop-volume liquid biopsy assays for real-time monitoring of cancer mutations included in ASCO 2016 BIRMINGHAM, Ala., May 20, 2016 (BUSINESS WIRE) – Circulogene Theranostics, the only biotechnology [...]

20 Apr, 2016

AACR 2016 Research Shows Circulogene Liquid Biopsy Excels at Real-Time Monitoring of Cancer Mutations

AACR 2016 Research Shows Circulogene Liquid Biopsy Excels at Real-Time Monitoring of Cancer Mutations Interlab comparison demonstrates Circulogene’s blood-drop-volume liquid biopsy assay is fastest, most accurate process to date for tracking and treating cancer BIRMINGHAM, Ala., – [...]

2 Mar, 2016

First International Orders for Cell-Free DNA Liquid Biopsy Testing Accepted

Circulogene Accepts First International Orders for Cell-Free DNA Liquid Biopsy Testing Single-blood-drop, high-yield DNA testing drives international demand for Circulogene’s fast, accurate, cancer monitoring and treatment products BIRMINGHAM, Ala., March 2, 2016 (BUSINESS WIRE) – Circulogene Theranostics, [...]

10 Feb, 2016

Circulogene Theranostics, UAB Comprehensive Cancer Center Join Forces, Announce Research Agreement

Circulogene Theranostics, UAB Comprehensive Cancer Center Announce Research Agreement   BIRMINGHAM, Ala., February 10, 2016 (BUSINESS WIRE) ­­­– Circulogene Theranostics, the only biotechnology company able to enrich circulating cell-free DNA (cfDNA) from a single blood drop for patient-specific [...]

5 Jan, 2016

Circulogene Theranostics Names James A. Posey III, M.D., as Chief Medical Advisor

Circulogene Theranostics Names James A. Posey III, M.D., as Chief Medical Advisor BIRMINGHAM, Ala., January 5, 2016 (BUSINESS WIRE)--Circulogene Theranostics the only biotechnology company able to enrich circulating cell-free DNA (cfDNA) from a single blood drop [...]

10 Nov, 2015

Circulogene Launches Liquid Biopsy Product Into Market

Proprietary Finger-Stick Cancer Monitoring Technology Launches Circulogene Theranostics into Liquid Biopsy Market Breakthrough, cell-free DNA testing method enables fast, accurate, personalized cancer monitoring and treatment guidance with a single blood drop BIRMINGHAM, Ala., November 10, [...]